

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re United States Patent Application of:)	Docket No.:	014811-673.119 US
Applicant(s):)	Examiner:	Phyllis G. Spivack
Application No.:)	Art Unit:	1614
Filing Date:)	Confirmation No:	8968
Title:)	Customer No.	
METHODS AND COMPOSITIONS)		
EMPLOYING)		
AMINOPHENYLACETIC ACID)		
COMPOUNDS)		
)		24239

RESPONSE TO JUNE 21, 2011 OFFICE COMMUNICATION ISSUED IN U.S. PATENT APPLICATION NO. 10/594,046

Mail Stop Amendment
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Sir:

In response to the June 21, 2011 Office Communication, applicants provide an interview summary of the telephonic conversation with Examiner Spivack wherein it was decided to and the term “and” after the clause “non-azo bonded 4-APAA compound;” so that claim 1 reads as follows:

1. A pharmaceutical composition comprising:
 - a first therapeutic agent selected from the group consisting of:
 - azo-bonded 4-aminophenylacetic acid (4-APAA) compound;
 - non-azo bonded 4-APAA compound; and
 - azo-bonded 5-aminosalicylic acid (5-ASA) compound;
 - non-azo bonded 5-ASA compound; and
 - a second therapeutic agent comprising a
 - 4-APAA compound azo bonded to a 5-ASA compound.